Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

  • This share is currently suspended. It was suspended at a price of 0.75
  • There is currently no data for BELL

Notice of AGM

2 Aug 2024 07:00

RNS Number : 8752Y
Belluscura PLC
02 August 2024
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Belluscura plc

("Belluscura" or the "Company" or "Group")

 

 Notice of AGM

 

LONDON, U.K. AND PLANO, TX, U.S. (2 August 2024). Belluscura plc (AIM:BELL), announces that the Notice of Annual General Meeting ("AGM"), to be held at 12.00 p.m on Tuesday 27 August 2024, is being posted to shareholders and will shortly be available on the Company's website at: https://investors.belluscura.com/investors/shareholder-information.

 

The Annual Report and Accounts for the year ended 31 December 2023 is available on the Company's website at: https://www.belluscura.com/financials/annual-and-interim-reports/

 

If you wish to submit a proxy vote for this meeting, please submit your vote online at www.signalshares.com. For your vote to be valid please ensure that it is received by no later than 12.00 p.m. on 25 August 2024. Alternatively, should you wish to vote via the CREST system, please see the instructions in the Notice of Meeting.

 

 

 

For further information please contact:

Belluscura plc

Tel: +44 (0)20 3128 8100

Adam Reynolds, ChairmanRobert Rauker, Chief Executive OfficerSimon Neicheril, Chief Financial Officer

SPARK Advisory Partners Limited

Nominated Adviser

Tel: +44 (0)20 3368 3550

Neil Baldwin / Jade Bayat

Dowgate Capital Limited

Broker

Tel: +44 (0)20 3903 7715

James Serjeant / Russell Cook

MHP

Financial PR & Investor Relations

Tel: +44 (0)20 3128 8100

email: Belluscura@mhpgroup.com

Katie Hunt/Matthew Taylor

 

 

 

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAFZGGRKMDGDZM
Date   Source Headline
2nd Dec 20257:00 amRNSCancellation - Belluscura plc
5th Nov 20259:47 amRNSIntention to appoint Administrator Update
31st Oct 202512:15 pmRNSIntention to appoint Administrator
30th Oct 202511:30 amRNSReplacement Statement re US Subsidiary Update
30th Oct 202510:38 amRNSStatement re US Subsidiary Chapter 7 Update
28th Oct 20255:32 pmRNSUpdate re Proposed Fundraise
22nd Sep 20257:00 amRNSDirectorate Change
12th Sep 20254:57 pmRNSBoard Appointment
26th Aug 20256:00 pmRNSSuspended Companies Notice - Deletion
11th Aug 20257:00 amRNSUpdate re Strategic Review and Proposed Fundraise
1st Jul 20257:30 amRNSSuspension - Belluscura PLC
30th Jun 20257:00 amRNSStrategic Review Update and Proposed Fundraising
19th Jun 202511:07 amRNSHolding(s) in Company - Replacement
18th Jun 20255:01 pmRNSHolding(s) in Company
13th May 202512:54 pmRNSResponse to Share Price Movement
9th May 20257:00 amRNSTrading update & commencement of strategic review
16th Apr 20257:00 amRNSTrading Update and Directorate Change
8th Apr 20252:45 pmRNSHolding(s) in Company
8th Apr 20257:00 amRNSStatement re proposed imposition of Tariffs
27th Mar 20253:15 pmRNSHolding(s) in Company
10th Mar 20255:49 pmRNSHolding(s) in Company
6th Mar 20254:21 pmRNSHolding(s) in Company
6th Mar 20251:08 pmRNSHolding(s) in Company
5th Mar 20252:21 pmRNSHolding(s) in Company
4th Mar 20253:50 pmRNSHolding(s) in Company
28th Feb 20253:44 pmRNSReplacement: Result of General Meeting
28th Feb 20251:32 pmRNSResult of General Meeting
13th Feb 20257:30 amRNSHolding(s) in Company
12th Feb 20257:00 amRNSPosting of Circular and Notice of General Meeting
11th Feb 20257:00 amRNSResult of oversubscribed WRAP Retail Offer
7th Feb 20257:05 amRNSLaunch of WRAP Retail Offer
7th Feb 20257:00 amRNSResult of Share Placing
6th Feb 20255:22 pmRNSProposed Share Placing
5th Feb 20257:30 amRNSRule 19.6(c) confirmation of post-offer intentions
20th Dec 20243:20 pmRNSAppointment of Allenby Capital as Joint Broker
11th Dec 20243:21 pmRNSHolding(s) in Company
22nd Nov 20247:00 amRNSNew $4million Credit Facility
12th Nov 20244:34 pmRNSHolding(s) in Company
28th Oct 20247:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
13th Sep 20241:37 pmRNSHolding(s) in Company
12th Sep 20243:05 pmRNSHolding(s) in Company
27th Aug 20242:17 pmRNSResult of General Meeting
27th Aug 20247:00 amRNSAGM Trading Statement
2nd Aug 20247:00 amRNSNotice of AGM
31st Jul 20241:11 pmRNSTotal Voting Rights
19th Jul 202410:36 amRNSDirector/PDMR Shareholding
11th Jul 202411:30 amRNSDirectorate Change
8th Jul 202412:45 pmRNSResult of General Meeting
4th Jul 20241:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.